Works matching DE "MULTIPLE myeloma treatment"
Results: 1776
Potential of Revlimid.
- Published in:
- Practice Nursing, 2010, v. 21, n. 1, p. 47
- Publication type:
- Article
Stem Cell Transplants for Multiple Myeloma: Is it Right for Me?
- Published in:
- Blood & Marrow Transplant Newsletter, 2009, v. 19, n. 1, p. 1
- Publication type:
- Article
Occlusal Palliation of a Hematopoietic Stem Cell Transplant Patient.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Methodological aspects of health‐related quality of life measurement and analysis in patients with multiple myeloma.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 15, p. 11, doi. 10.1111/bjh.15759
- By:
- Publication type:
- Article
Infectious and immunological sequelae of daratumumab in multiple myeloma.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 15, p. 187, doi. 10.1111/bjh.15433
- By:
- Publication type:
- Article
HAX‐1 overexpression in multiple myeloma is associated with poor survival.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 15, p. 179, doi. 10.1111/bjh.15430
- By:
- Publication type:
- Article
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.
- Published in:
- Clinical & Experimental Nephrology, 2012, v. 16, n. 5, p. 659, doi. 10.1007/s10157-012-0684-5
- By:
- Publication type:
- Article
Galectin-8 enhances adhesion of multiple myeloma cells to vascular endothelium and is an adverse prognostic factor.
- Published in:
- Glycobiology, 2016, v. 26, n. 10, p. 1048, doi. 10.1093/glycob/cww066
- By:
- Publication type:
- Article
The Real World Effectiveness of Hematopoietic Transplant Among Elderly Individuals With Multiple Myeloma.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2015, v. 107, n. 8, p. 1, doi. 10.1093/jnci/djv139
- By:
- Publication type:
- Article
The Real World Effectiveness of Hematopoietic Transplant Among Elderly Individuals With Multiple Myeloma.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2015, v. 107, n. 8, p. 1, doi. 10.1093/jnci/djv139
- By:
- Publication type:
- Article
FDA Approves New Agent for Multiple Myeloma.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2015, v. 107, n. 6, p. 5, doi. 10.1093/jnci/djv165
- By:
- Publication type:
- Article
Treating Multiple Myeloma: The Cause for Optimism.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 5, p. 6, doi. 10.1093/jnci/dju140
- By:
- Publication type:
- Article
Thirteenth Biannual Report of the Cochrane Haematological Malignancies Group—Focus on Multiple Myeloma.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 17, p. E1, doi. 10.1093/jnci/djr271
- By:
- Publication type:
- Article
Researchers Debate Best Use of Stem Cell Transplants in Patients With Multiple Myeloma.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2009, v. 101, n. 23, p. 1608, doi. 10.1093/jnci/djp434
- By:
- Publication type:
- Article
Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2009, v. 101, n. 20, p. 1430, doi. 10.1093/jnci/djp320
- By:
- Publication type:
- Article
Gene Mutation Revelation Points to New Target for Myeloma Treatment, Studies Say.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2007, v. 99, n. 18, p. 1362, doi. 10.1093/jnci/djm164
- By:
- Publication type:
- Article
Bortezomib May Be More Effective, but More Toxic, for Multiple Myeloma.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2005, v. 97, n. 14, p. 1031
- By:
- Publication type:
- Article
Missing the target: ubiquitin ligase drugs stall.
- Published in:
- 2005
- By:
- Publication type:
- journal article
Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2017, v. 32, n. 1, p. 865, doi. 10.1080/14756366.2017.1334649
- By:
- Publication type:
- Article
Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma.
- Published in:
- Oncologist, 2007, v. 12, n. 8, p. 978, doi. 10.1634/theoncologist.12-8-978
- By:
- Publication type:
- Article
What do we learned from new treatment of multiple myeloma?
- Published in:
- Macedonian Pharmaceutical Bulletin / Makedonsko Farmacevtski Bilten, 2016, v. 62, p. 529
- By:
- Publication type:
- Article
First-in-Human CAR T-Cell Trial Shows Activity in Multiple Myeloma.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 93
- By:
- Publication type:
- Article
Multiple Myeloma and the MMRF CoMMpass Study: Revolutionizing Clinical Trial Data Dissemination.
- Published in:
- 2013
- By:
- Publication type:
- Interview
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 5, p. 1, doi. 10.1038/s41408-021-00490-8
- By:
- Publication type:
- Article
Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 3, p. 1, doi. 10.1038/s41408-021-00441-3
- By:
- Publication type:
- Article
Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 3, p. 1, doi. 10.1038/s41408-021-00440-4
- By:
- Publication type:
- Article
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Preclinical development of CD126 CAR-T cells with broad antitumor activity.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41408-020-00405-z
- By:
- Publication type:
- Article
Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41408-020-00400-4
- By:
- Publication type:
- Article
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41408-020-00397-w
- By:
- Publication type:
- Article
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41408-020-00390-3
- By:
- Publication type:
- Article
Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 2, p. 1, doi. 10.1038/s41408-020-0283-8
- By:
- Publication type:
- Article
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 2, p. 1, doi. 10.1038/s41408-020-0273-x
- By:
- Publication type:
- Article
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 12, p. 1, doi. 10.1038/s41408-019-0254-0
- By:
- Publication type:
- Article
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 10, p. N.PAG, doi. 10.1038/s41408-019-0245-1
- By:
- Publication type:
- Article
In response to: Treatment of patients with multiple myeloma progressing on frontline therapy with lenalidomide, Moreau et al., 2019.
- Published in:
- 2019
- By:
- Publication type:
- Letter to the Editor
A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 9, p. N.PAG, doi. 10.1038/s41408-019-0228-2
- By:
- Publication type:
- Article
Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 8, p. N.PAG, doi. 10.1038/s41408-019-0219-3
- By:
- Publication type:
- Article
Anti-myeloma Effects of Icariin Are Mediated Through the Attenuation of JAK/STAT3-Dependent Signaling Cascade.
- Published in:
- Frontiers in Pharmacology, 2018, p. 1, doi. 10.3389/fphar.2018.00531
- By:
- Publication type:
- Article
Long-Term Efficacy of Maintenance Therapy for Multiple Myeloma: A Quantitative Synthesis of 22 Randomized Controlled Trials.
- Published in:
- Frontiers in Pharmacology, 2018, p. 1, doi. 10.3389/fphar.2018.00430
- By:
- Publication type:
- Article
Sanguinarine Induces Apoptosis Pathway in Multiple Myeloma Cell Lines via Inhibition of the JaK2/STAT3 Signaling.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00285
- By:
- Publication type:
- Article
MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00249
- By:
- Publication type:
- Article
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00045
- By:
- Publication type:
- Article
Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
- Published in:
- Clinical & Experimental Immunology, 2012, v. 170, n. 2, p. 167, doi. 10.1111/j.1365-2249.2012.04642.x
- By:
- Publication type:
- Article
Upper Gastrointestinal Bleeding from Gastric Amyloidosis in a Patient with Smoldering Multiple Myeloma.
- Published in:
- Case Reports in Gastrointestinal Medicine, 2015, v. 2015, p. 1, doi. 10.1155/2015/320120
- By:
- Publication type:
- Article
FORGIVE SINS: RISE OF THALIDOMIDE.
- Published in:
- Our Dermatology Online / Nasza Dermatologia Online, 2014, v. 5, n. 2, p. 190, doi. 10.7241/ourd.20142.48
- By:
- Publication type:
- Article